Pulse-duration scaling of ultrafast laser-induced damage threshold in hybrid gratings
Optics Letters · 01.08.2026 · 51 (15) · 4236
DOI: 10.1364/ol.608170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Optics Letters, online erschienen am 23.07.2026. Verfasst von Ziyao Su und 1 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Office of Accelerator R&D and Production, United States Air Force Office of Scientific Research.
Abstract (Originalsprache)
High damage threshold gratings are in demand worldwide as critical components for next-generation ultrahigh-intensity lasers. Here, we investigate the pulse-duration dependence of ultrafast laser-induced damage thresholds (LIDT) in hybrid multilayer dielectric gratings, touted to combine superior performance properties of both metallic and multilayer dielectric (MLD) gratings, using a dynamic finite-difference time-domain model incorporated with linear and non-linear absorption models. Simulations agree with reported experimental LIDT values for three representative designs and predict scaling exponents that vary with pulse durations ranging from 10 to 500 fs. The results reveal strong dependence on both material bandgap and grating field distribution, providing guidance for designing high LIDT gratings.
Förderung
- Office of Accelerator R&D and Production
- United States Air Force Office of Scientific Research
Zitieren
APA
Su, Z., & Chowdhury, E. A. (2026). Pulse-duration scaling of ultrafast laser-induced damage threshold in hybrid gratings. Optics Letters, 51(15), 4236. https://doi.org/10.1364/ol.608170
Vancouver
Su Z, Chowdhury EA. Pulse-duration scaling of ultrafast laser-induced damage threshold in hybrid gratings. Optics Letters. 2026;51(15):4236. doi:10.1364/ol.608170
BibTeX
@article{Su2026,
author = {Su, Ziyao and Chowdhury, Enam A},
title = {Pulse-duration scaling of ultrafast laser-induced damage threshold in hybrid gratings},
journal = {Optics Letters},
year = {2026},
volume = {51},
number = {15},
pages = {4236},
doi = {10.1364/ol.608170}
}
EUVIMED